US FDA Approved RINVOQ To Treat Adults With Active Ankylosing Spondylitis
The Food and Drug Administration (FDA) of the United States has approved RINVOQ for the purpose of treating the adults suffering with the active Ankylosing spondylitis (AS), who have been having an inadequate response or the intolerance to more tumor necrosis factor (TNF) blockers. Thomas Hudson, senior vice president and MD, research and development at […]
Continue Reading